Results 81 to 90 of about 4,918 (159)

Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment. [PDF]

CPT Pharmacometrics Syst Pharmacol
Dias BB, Olivo LB, de Araújo BV.
europepmc   +1 more source

Simple and cost-effective UV spectrophotometric platforms integrating advanced green and blue metrics for concurrent analysis of dapagliflozin and vildagliptin in diabetes therapy. [PDF]

Sci Rep
Darweish E, Hashem HA, Nasr R, Bahgat EA.   +3 more
europepmc   +1 more source

ERRATUM: Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction. [PDF]

J Endocrinol
Apaijai N, Inthachai T, Lekawanvijit S, Chattipakorn SC, Chattipakorn N.   +4 more
europepmc   +1 more source

Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan. [PDF]

Drugs Real World Outcomes
Takami A, Terashima G, Tajima T, Yamashita K, Igarashi A.   +4 more
europepmc   +1 more source

Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Zhu X, Wang X, Zhang P, Yang Z, Zhao N, Li J, Shi Y, Zhao Y, Ma J.   +8 more
europepmc   +1 more source

Effectiveness and Safety of a Fixed-Dose Combination of Dapagliflozin and Vildagliptin in the Treatment of Type 2 Diabetes Mellitus: A Retrospective Study. [PDF]

Cureus
Sanghvi A, Warrier S.
europepmc   +1 more source

Comparative Evaluation of the Effects of Oral Anti-hyperglycemic Agents and an Ayurvedic Hepatoprotective Agent in a Rat Model of Non-alcoholic Fatty Liver Disease (NAFLD). [PDF]

Cureus
Kalra SSS, Sadasivam B, Najmi A, Chaurasia JK.   +3 more
europepmc   +1 more source

Correction: Fabrication of novel vildagliptin loaded ZnO nanoparticles for anti diabetic activity. [PDF]

Sci Rep
Samad A, Shahid S, Mansoor S, Afzal S, Javed M, Zidan A, Shoaib A, Jaber F, Iqbal S, Saad M, Mahmood S, Awwad NS, Ibrahium HA.   +12 more
europepmc   +1 more source

Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). [PDF]

PLoS One
Xiong W, Li Y, Huang J, He G, Sun J.
europepmc   +1 more source

Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records. [PDF]

BMC Pharmacol Toxicol
Hayakawa T, Akimoto H, Nagashima T, Minagawa K, Takahashi Y, Asai S.   +5 more
europepmc   +1 more source